Press Releases Ypsomed Group

We are monitoring the global development after the outbreak of the Coronavirus very closely. Our highest priority is our business continuity and the reliable supply of our products as well as the safety of our employees. We can confirm that to date there is no impact on the supply of our products and that our production sites are fully operational.

Press Releases Ypsomed Group

Burgdorf – Ypsomed is recording weaker growth in the insulin pump business and is adjusting its approval strategy with the American FDA. In addition, Ypsomed is reducing its EBIT outlook for the current financial year 2019/20 to CHF 9 million due to one-time and temporary effects. Ypsomed confirms its mid-term EBIT target of CHF 100 million.

Montréal, Canada - The Ministry of Health of the Canadian Ontario region has added the YpsoPump® insulin pump to its list of approved devices funded by the Assistive Device Program (ADP). As of 13 January 2020, the YpsoPump® is officially reimbursed in the Ontario region and can be prescribed by health care professionals to people with diabetes that qualify for insulin pump therapy under the ADP.

Market entry of YpsoMate autoinjector for Teribone™ in Japan
Teribone™ autoinjector

Press Releases Ypsomed Group

Burgdorf – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJEX™ syringe with the drug Teribone™ and assemble it with the YpsoMate prefilled autoinjector from Ypsomed. Teribone™ is a Teriparatide for the treatment of osteoporosis. The drug was developed by Asahi Kasei Pharma (AKP) and will be launched in Japan.